Tardive Dyskinesia Therapeutics Market Size In 2026: Regional Growth, Key Segments And Future Outlook
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Tardive Dyskinesia Therapeutics Market Growth From $3.34 Billion In 2026 To $4.39 Billion By 2030 At A CAGR Of 7%
The tardive dyskinesia therapeutics market size has seen strong expansion in recent years. Its valuation is anticipated to increase from $3.12 billion in 2025 to $3.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The surge observed in the past can be ascribed to factors including the scarcity of treatment alternatives for tardive dyskinesia, the reliance on conventional antipsychotic therapies, insufficient patient knowledge, the rising frequency of antipsychotic drug use, and a limited availability of specialized treatment facilities.
The tardive dyskinesia therapeutics market is anticipated to experience substantial expansion in the coming years. It is projected to reach a valuation of $4.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This projected increase during the forecast period stems from the advancement of new therapeutic options for tardive dyskinesia, a rise in research and development investments in neurological disorders, a growing inclination towards homecare settings, the establishment of more specialty treatment centers, improved patient monitoring, and the adoption of digital therapeutics. Significant trends foreseen for this period encompass the increased uptake of deutetrabenazine and valbenazine, an amplified focus on customized neurological therapies, the broadening availability of homecare and remote treatment solutions, heightened awareness regarding drug-induced tardive dyskinesia, and a strong emphasis on treatment safety and adherence in the long term.
Get A Free Sample Report With In-Depth Market Insights:
Tardive Dyskinesia Therapeutics Market Growth Momentum: What Factors Are Shaping Demand?
The escalating incidence of mental health conditions is projected to stimulate the expansion of the tardive dyskinesia therapeutics market moving forward. These disorders are defined as illnesses impacting an individual’s cognition, feelings, conduct, or daily functionality, frequently leading to considerable discomfort or challenges in everyday living. The surge in mental health issues stems from heightened social isolation, with the move to digital interactions and rapid lifestyles diminishing valuable face-to-face contacts, thereby fostering increased loneliness and emotional stress. Tardive dyskinesia therapeutics assist patients with mental disorders by controlling involuntary movements resulting from extended antipsychotic medication, which in turn enhances compliance with treatment and general well-being. For instance, in 2024, according to the National Alliance On Mental Illness, a US-based organization, among people in the U.S. aged 18-44, psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations each year. Consequently, the growing occurrence of mental health disorders is a key factor propelling the tardive dyskinesia therapeutics market.
Tardive Dyskinesia Therapeutics Market Segmentation And Category Overview
The tardive dyskinesia therapeutics market covered in this report is segmented –
1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs
2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form
3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia
4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings
Subsegments:
1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel
2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel
3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration
Tardive Dyskinesia Therapeutics Market Trends Redefining Industry Growth
Leading companies in the tardive dyskinesia therapeutics market are concentrating on developing advanced products, such as once-daily treatment options, to assist in maintaining more consistent drug levels in the body. Once-daily treatment options refer to medications or therapies designed for a single daily intake, thereby simplifying dosing schedules and enhancing patient adherence. For instance, in May 2024, Teva Pharmaceutical Industries Limited, an Israel-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for AUSTEDO XR tablets, intended for treating adults with tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. This recent approval of AUSTEDO XR presents patients with proven effectiveness in managing involuntary movements, alongside the added convenience of a once-daily, single-pill dosage. This new formulation provides clinically therapeutic doses, confirmed by pivotal clinical trials. Additionally, it is now offered in four distinct tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.
Tardive Dyskinesia Therapeutics Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the tardive dyskinesia therapeutics market are Neurocrine Biosciences Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation, AbbVie Inc., Pfizer Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Zydus Lifesciences Ltd., Lupin Limited, Amneal Pharmaceuticals Inc., Lannett Company Inc., Alembic Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals PLC, Accord Healthcare Ltd., Cipla Ltd., Glenmark Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Indivior PLC, Viatris Inc., Alkem Laboratories Ltd., Intas Pharmaceuticals Ltd., Som Biotech Ltd., Addex Therapeutics Ltd., Luye Pharma Group Ltd., Apotex Inc., Sandoz Group AG, Torrent Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Taro Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd.
View The Full Tardive Dyskinesia Therapeutics Market Report:
Tardive Dyskinesia Therapeutics Market Regional Analysis And Leading Geography
North America was the largest region in the tardive dyskinesia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
